Research programme: cancer therapeutics - Verastem

Drug Profile

Research programme: cancer therapeutics - Verastem

Alternative Names: Salinomycin - Verastem; VS-507; VS-5095; VS-6062

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Broad Institute; Massachusetts Institute of Technology; S*BIO
  • Developer Verastem
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Stem cell inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Mar 2016 Verastem has worldwide patent protection for VS 6062 (Verastem form 10-K, March 2016).
  • 11 Sep 2013 Preclinical development is ongoing in the US
  • 09 Nov 2012 Pharmacodynamics data from a preclinical trial in Cancer presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics (EORTC-NCI-AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top